This Too… Will Be Immaterial.

We should expect that not every combo study will reach statistical significance.

And so it goes -- this time, it was in patients with advanced or recurrent endometrial carcinoma -- in a combo with Esai's latest.

Keytruda is and will remain the world's highest revenue drug franchise.

Onward, grinning -- into a sunny Friday morning. . . .

नमस्ते